Podcast

MPN Heroes Make a Difference in the Rare Blood Cancer Space

Author(s):

Brielle Benyon

In this week's episode of the CURE Talks Cancer podcast, hear from some of our recent MPN Heroes.

For this week's episode, hear from some of CURE's 2018 MPN Heroes. These Heroes are patients, survivors, caregivers, advocates or health care professionals with a passion for improving the lives and outcomes of patients with myeloproliferative neoplasms.

You'll hear from Angela Fleischman, M.D., Ph.D., Lori Jemison, RN, Marcy Worthington, Richard French, Jaden Presaud, Celia Miltz, Jean Diesch and Rebecca Shapiro and Molly Guy.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of Dr. Tiziano Barbui
Image of doctor.
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Image of Crispino
Picture of Joy Anderson
Image of doctor.
Dr. Richard “Rick" Winneker
Image of man with grey hair.
Related Content
Image of blood cells.
June 11th 2025

Rusfertide Reduces Phlebotomy Need, Improves Quality of Life in Polycythemia Vera

Ryan Scott
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
blood cells.
May 29th 2025

Pelabresib and Rituxan Combo Improves Outcomes in Myelofibrosis

Ryan Scott
A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with myelofibrosis.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of blood cells.
May 6th 2025

Givinostat Wins U.S. FDA Fast Track Designation for Patients With PV

Ryan Scott
Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for patients with polycythemia vera.
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis: © stock.adobe.com
April 19th 2025

Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis

Alex Biese
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.